MedTrace Logo

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

NCT00755885 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2017-01-26

No results posted yet for this study

Summary

RATIONALE: Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I/II trial is studying the side effects and best dose of abiraterone acetate and to see how well it works in treating postmenopausal women with advanced or metastatic breast cancer.

Conditions

Interventions

DRUG

abiraterone acetate

OTHER

laboratory biomarker analysis

OTHER

pharmacogenomic studies

Sponsors & Collaborators

Principal Investigators

  • Johann Sebastian de Bono, MD · Cancer Research UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2016-06-04
Completion
2016-06-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00755885 on ClinicalTrials.gov